ResearcherUniversity of HelsinkiActive in the last 2 years
Riitta Lassila
Matched on ORCID iD 0000-0002-1911-3094; OpenAlex author ID A5051498958. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 10
2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 6
- Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma. First author DOI 10.1002/cam4.71954↗
- Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohort study. Co-author DOI 10.1002/cam4.70014↗
- Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. Co-author DOI 10.1002/cam4.4397↗
- Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreatic cancer patients. Last author DOI 10.1016/j.thromres.2020.12.018↗
- CA 19-9 doubling time in pancreatic cancer as a predictor of venous thromboembolism: a hospital database study. Co-author DOI 10.1080/0284186x.2019.1679881↗
- Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1177/1076029618779133↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hanna E. Seppänen · 6 shared papers, 2018–2026 · strength 1.18
- Paper Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Tre… DOI 10.1002/cam4.71954↗
- Paper Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohor… DOI 10.1002/cam4.70014↗
- Paper Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. DOI 10.1002/cam4.4397↗
- Caj H. Haglund · 5 shared papers, 2018–2026 · strength 1.03
- Paper Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Tre… DOI 10.1002/cam4.71954↗
- Paper Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohor… DOI 10.1002/cam4.70014↗
- Paper Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. DOI 10.1002/cam4.4397↗
- Nora Mattila · 4 shared papers, 2018–2026 · strength 0.80
- Paper Preoperative Biomarker Panel With Fibrinogen, FVIII, and CA 19-9 as a Tool for Prognostic Evaluation in Neoadjuvant-Tre… DOI 10.1002/cam4.71954↗
- Paper Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer. DOI 10.1002/cam4.4397↗
- Paper Levels of the cancer biomarker CA 19-9 are associated with thrombin generation in plasma from treatment-naïve pancreati… DOI 10.1016/j.thromres.2020.12.018↗
- Olli Carpén · 2 shared papers, 2020–2024 · strength 0.37
- Paper Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohor… DOI 10.1002/cam4.70014↗
- Paper CA 19-9 doubling time in pancreatic cancer as a predictor of venous thromboembolism: a hospital database study. DOI 10.1080/0284186x.2019.1679881↗
- Panu Aaltonen · 1 shared paper, 2024 · strength 0.23
- Pauli Antero Puolakkainen · 1 shared paper, 2024 · strength 0.23
- Annika Eurola · 1 shared paper, 2022 · strength 0.19
- Maija H. Peippo · 1 shared paper, 2020 · strength 0.15
- Nigel Mackman · 1 shared paper, 2021 · strength 0.13
- Yohei Hisada · 1 shared paper, 2021 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.